Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder (Beacon)

Ethicon

Status

Completed

Conditions

Overactive Bladder

Treatments

Device: Sham version of (VERV™ System)

Device: (VERV™ System)

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01369485

CI-10-0009

Details and patient eligibility

About

The purpose of this study is to evaluate the change from baseline between the active and sham treatment groups in the treatment of urgency (urinary) incontinence episodes (leaks).

Enrollment

163 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Males and Females, at least 18 years of age
Failure on primary OAB treatment, such as behavior modification or fluid/diet management, AND at least one (1) anti-cholinergic drug (unless patient was contra-indicated for anti-cholinergic use)
Symptoms of overactive bladder for at least 6 months
An average of one (1) or more urgency (urinary) incontinence episodes per 24-hours, over a 3-day period, confirmed by the 3-day baseline voiding diary, with a maximum of 12 urgency (urinary) incontinence episodes per 24-hours
Dexterity and ability to place and operate the device
Females of child-bearing capability agrees to use a reliable form of birth control for the duration of the trial
An average of eight (8) or more voids per 24-hours, over a 3-day period, confirmed by the 3-day baseline voiding diary
Willing and capable of understanding and complying with all requirements of the protocol, including proper completion of the baseline voiding diary
Signed and dated the IRB-approved Informed Consent document.

Exclusion criteria

Dysfunctional voiding symptoms unrelated to OAB, such as clinically significant bladder outlet obstruction, and urinary retention (pvr > 100 cc)
Morbidly obese, defined as having Body Mass Index (BMI) > 40 kg/m2
Stress predominant mixed urinary incontinence
Neurological disease affecting urinary bladder function, including but not limited to Parkinson's disease, multiple sclerosis, stroke, spinal cord injury and uncontrolled epilepsy.
Pelvic surgery (such as sub-urethral sling, pelvic floor repair) within the past 6 months
Intravesical or urethral sphincter Botulinum Toxin Type A injections within the past 12 months
Any neuromodulation therapy for overactive bladder within the past 3 months
Failure to respond to previous neuromodulation therapy for overactive bladder
Leading edge of any vaginal prolapse is beyond hymenel ring.
Prior peri-urethral or transurethral bulking agent injections for bladder problems within the past 12 months.
Any skin conditions affecting treatment or assessment of the treatment sites
History of lower back surgery or injury that could impact placement of the patch, or where underlying scar tissue or nerve damage may impact treatment.
Presence of an implanted electro-medical device (e.g. pacemaker, defibrillator, InterStim®, etc.), or any metallic implant in the lower back.
Pregnant, nursing, suspected to be pregnant (by urine pregnancy method), or plans to become pregnant during the course of the study.
Known latex allergies, or allergies or hypersensitivity to patch materials that will be in contact with the body (e.g., hydrogel, acrylic-based adhesive, polyurethane).
Uncontrolled diabetes and/or diabetes with peripheral neuropathy.
Current Urinary Tract Infection (UTI) or history of recurrent UTIs (>3 UTIs in the past year).
History of lower tract genitourinary malignancies within the last 6 months or any previous pelvic radiation.
Any clinically significant systemic disease or condition that in the opinion of the Investigator would make the patient unsuitable for the study.